These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
878 related articles for article (PubMed ID: 22821179)
1. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer. Wang M; Zhao J; Zhang LM; Li H; Yu JP; Ren XB; Wang CL J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179 [TBL] [Abstract][Full Text] [Related]
2. [Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer]. Wang M; Zhang L; Zhao X; Liu J; Chen Y; Wang C Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):651-6. PubMed ID: 25564053 [TBL] [Abstract][Full Text] [Related]
3. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374 [TBL] [Abstract][Full Text] [Related]
12. Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma. Pirazzoli V; Ayeni D; Meador CB; Sanganahalli BG; Hyder F; de Stanchina E; Goldberg SB; Pao W; Politi K Clin Cancer Res; 2016 Jan; 22(2):426-35. PubMed ID: 26341921 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Yang Z; Zhang SL; Hu X; Tam KY Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498 [TBL] [Abstract][Full Text] [Related]
14. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines. Cavazzoni A; Alfieri RR; Cretella D; Saccani F; Ampollini L; Galetti M; Quaini F; Graiani G; Madeddu D; Mozzoni P; Galvani E; La Monica S; Bonelli M; Fumarola C; Mutti A; Carbognani P; Tiseo M; Barocelli E; Petronini PG; Ardizzoni A Mol Cancer; 2012 Dec; 11():91. PubMed ID: 23234355 [TBL] [Abstract][Full Text] [Related]
15. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor. Li S; Liu Z; Zhu F; Fan X; Wu X; Zhao H; Jiang L Oncol Res; 2013; 21(3):137-44. PubMed ID: 24512728 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737 [TBL] [Abstract][Full Text] [Related]
17. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722 [TBL] [Abstract][Full Text] [Related]
18. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. Li F; Zhu T; Cao B; Wang J; Liang L Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888 [TBL] [Abstract][Full Text] [Related]
19. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells. Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520 [TBL] [Abstract][Full Text] [Related]